再発寛解型多発性硬化症の世界市場レポート 2025年

再発寛解型多発性硬化症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR4.8％で58億1,000万米ドルに成長します。予測期間中の成長は、個別化医療の採用の増加、バイオマーカー研究への注目の高まり、新規治療アプローチへの投資の増加、疾病管理におけるAIの利用拡大、革新的治療への規制支援などに起因すると考えられます。この期間に予想される主な動向には、遺伝子・細胞治療の出現、経口疾患修飾療法へのシフト、血液脳関門ドラッグデリバリーシステムの進歩、疾患修飾療法の進歩、次世代モノクローナル抗体の開発などがあります。

個別化医療の採用拡大が、再発寛解型多発性硬化症（RRMS）市場の拡大を牽引すると予想されます。個別化医療は、個人の遺伝的、環境的、ライフスタイル的要因に合わせて治療や療法を調整し、ヘルスケアの成果を最適化するものです。このアプローチは、遺伝子の変異やバイオマーカーの正確な同定を可能にし、より的を絞った効果的な治療につながるゲノム配列決定の進歩により、支持を集めています。RRMSは、テーラーメイド治療が病気の進行、症状の重篤度、治療効果の個人差にどのように対応し、最終的に患者の転帰を改善するかを示すことで、個別化医療の重要性を強調しています。例えば、2024年2月、個別化医療を提唱する米国を拠点とする団体である個別化医療連合は、米国食品医薬品局が希少疾患患者のために16の新しい個別化治療を承認したと報告しました。その結果、個別化医療の採用拡大がRRMS市場の成長を後押ししています。

再発寛解型多発性硬化症市場の主要企業は、治療効果の向上、患者の転帰の改善、RRMSの標準治療の再定義を目指し、画期的なブロックバスター治療などの革新的な治療アプローチを開発しています。ブレイクスルー・ブロックバスター治療とは、医療を大幅に進歩させる非常に有効な治療法を指し、多くの場合、満たされていないニーズに対応したり、既存の治療法と比較して優れた治療成績をもたらしたりします。例えば、2024年2月、インドの製薬会社であるロシュ・プロダクツ（インド）社は、神経領域のポートフォリオを強化し、インドの患者のアンメット・メディカル・ニーズに応えるため、多発性硬化症（MS）の画期的な治療薬であるオクレバス（オクレリズマブ）を導入しました。オクレブスは、MSの進行に関与するCD20陽性B細胞を標的とし、再発を抑え、障害の進行を遅らせることを目指します。B細胞を選択的に枯渇させるユニークな作用機序により、オクレブスは疾患の経過を修正し、患者の長期転帰を改善します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界再発寛解型多発性硬化症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の再発寛解型多発性硬化症市場：成長率分析
• 世界の再発寛解型多発性硬化症市場の実績：規模と成長, 2019-2024
• 世界の再発寛解型多発性硬化症市場の予測：規模と成長, 2024-2029, 2034F
• 世界再発寛解型多発性硬化症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の再発寛解型多発性硬化症市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベータインターフェロン
• クラドリビン
• ジメチルフマル酸
• フィンゴリモド
• オザニモド
• その他の薬物の種類
• 世界の再発寛解型多発性硬化症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮下
• 静脈内
• 世界の再発寛解型多発性硬化症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫調節薬
• NrF2活性化剤
• インターフェロン
• その他の治療法
• 世界の再発寛解型多発性硬化症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の再発寛解型多発性硬化症市場、ベータインターフェロンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターフェロンβ-1a
• インターフェロンベータ1b
• 世界の再発寛解型多発性硬化症市場クラドリビンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口クラドリビン
• 注射用クラドリビン
• 世界の再発寛解型多発性硬化症市場ジメチルフマル酸のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• テクフィデラ
• ヴメリティ
• 世界の再発寛解型多発性硬化症市場フィンゴリモドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジレニアフィンゴリモド
• ジェネリックフィンゴリモド
• 世界の再発寛解型多発性硬化症市場オザニモドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゼポシア
• 世界の再発寛解型多発性硬化症市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナタリズマブ
• アレムツズマブ
• オクレリズマブ
• シポニモド
• テリフルノミド

第7章 地域別・国別分析

• 世界の再発寛解型多発性硬化症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の再発寛解型多発性硬化症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 再発寛解型多発性硬化症市場：競合情勢
• 再発寛解型多発性硬化症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• Novartis AG
• GSK plc
• Eli Lilly and Company
• Merck KGaA
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Eisai Co. Ltd.
• Genentech Inc.
• Hikma Pharmaceuticals LLC
• Glenmark Pharmaceuticals Limited
• CinnaGen Co
• Zenas BioPharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 再発寛解型多発性硬化症市場2029：新たな機会を提供する国
• 再発寛解型多発性硬化症市場2029：新たな機会を提供するセグメント
• 再発寛解型多発性硬化症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Relapsing-remitting multiple sclerosis (RRMS) is a chronic neurological condition characterized by recurring episodes of symptoms (relapses) followed by periods of partial or complete recovery (remissions). It occurs when the immune system attacks the myelin sheath, impairing nerve signal transmission in the central nervous system.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main drug types used to treat relapsing-remitting multiple sclerosis include beta-interferon, cladribine, dimethyl fumarate, fingolimod, ozanimod, and others. Beta-interferon helps regulate the immune system to reduce inflammation and slow damage to the nervous system. These drugs are administered through various routes, including subcutaneous and intravenous injections. Treatment options include immunomodulating drugs, NrF2 activators, interferons, and others, and are commonly used by healthcare providers in hospitals and clinics.

The relapsing-remitting multiple sclerosis market research report is one of a series of new reports from The Business Research Company that provides relapsing-remitting multiple sclerosis market statistics, including the relapsing-remitting multiple sclerosis industry global market size, regional shares, competitors with the relapsing-remitting multiple sclerosis market share, detailed relapsing-remitting multiple sclerosis market segments, market trends, and opportunities, and any further data you may need to thrive in the relapsing-remitting multiple sclerosis industry. This relapsing-remitting multiple sclerosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The relapsing-remitting multiple sclerosis market size has grown strongly in recent years. It will grow from$4.58 billion in 2024 to $4.81 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period can be attributed to the increasing prevalence of multiple sclerosis, greater awareness and early diagnosis, the expansion of healthcare infrastructure, rising government funding for neurological disorders, and improved patient access to treatment.

The relapsing-remitting multiple sclerosis market size is expected to see strong growth in the next few years. It will grow to$5.81 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth during the forecast period can be attributed to the rising adoption of personalized medicine, increased focus on biomarker research, growing investment in novel therapeutic approaches, expanded use of AI in disease management, and regulatory support for innovative treatments. Key trends expected during this period include the emergence of gene and cell therapies, a shift towards oral disease-modifying therapies, advancements in blood-brain barrier drug delivery systems, progress in disease-modifying therapies, and the development of next-generation monoclonal antibodies.

The growing adoption of personalized medicine is expected to drive the expansion of the relapsing-remitting multiple sclerosis (RRMS) market. Personalized medicine tailors treatments and therapies to an individual's genetic, environmental, and lifestyle factors, optimizing healthcare outcomes. This approach is gaining traction due to advancements in genomic sequencing, which enable the precise identification of genetic variations and biomarkers, leading to more targeted and effective treatments. RRMS emphasizes the importance of personalized medicine by demonstrating how tailored treatments can address individual variations in disease progression, symptom severity, and treatment response, ultimately improving patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization advocating for personalized medicine, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, up from just 6 in 2022. As a result, the growing adoption of personalized medicine is fueling the growth of the RRMS market.

Leading companies in the relapsing-remitting multiple sclerosis market are developing innovative treatment approaches, such as breakthrough blockbuster therapies, to improve treatment efficacy, enhance patient outcomes, and redefine the standard of care for RRMS. Breakthrough blockbuster therapy refers to highly effective treatments that significantly advance medical care, often addressing unmet needs or providing superior outcomes compared to existing therapies. For instance, in February 2024, Roche Products (India) Pvt. Ltd., an India-based pharmaceutical company, introduced Ocrevus (Ocrelizumab), a groundbreaking treatment for multiple sclerosis (MS), to strengthen its neurology portfolio and meet the unmet medical needs of patients in India. Ocrevus targets CD20-positive B cells, which contribute to MS progression, aiming to reduce relapses and slow disability advancement. With a unique mechanism of action that selectively depletes B cells, Ocrevus helps modify the disease course and improve long-term patient outcomes.

In January 2025, Cycle Pharmaceuticals Ltd., a UK-based biopharmaceutical company, acquired Banner Life Sciences for an undisclosed sum. This acquisition allows Cycle Pharmaceuticals to expand its portfolio of treatments for neurological disorders, including multiple sclerosis, and strengthens its position in the U.S. pharmaceutical market. Banner Life Sciences, a U.S.-based company, offers BAFIERTAM as a treatment for relapsing forms of multiple sclerosis, including relapsing-remitting MS.

Major players in the relapsing-remitting multiple sclerosis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Hikma Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, CinnaGen Co, and Zenas BioPharma Inc.

North America was the largest region in the relapsing-remitting multiple sclerosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in relapsing-remitting multiple sclerosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the relapsing-remitting multiple sclerosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The relapsing-remitting multiple sclerosis market consists of revenues earned by entities by providing services such as disease-modifying therapies (DMTs), immunosuppressants, and symptom management solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The relapsing-remitting multiple sclerosis market also includes sales of pharmaceuticals, assistive devices, and diagnostic tools used in disease management and monitoring. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Relapsing-Remitting Multiple Sclerosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on relapsing-remitting multiple sclerosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for relapsing-remitting multiple sclerosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The relapsing-remitting multiple sclerosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Beta-Interferon; Cladribine; Dimethyl Fumarate; Fingolimod; Ozanimod; Other Drug Types
• 2) By Route Of Administration: Subcutaneous; Intravenous
• 3) By Treatment: Immunomodulating Drugs; NrF2 Activators; Interferons; Other Treatments
• 4) By End-User: Hospitals; Clinics; Other End-Users
• Subsegments:
• 1) By Beta-Interferon: Interferon Beta-1a; Interferon Beta-1b
• 2) By Cladribine: Oral Cladribine; Injectable Cladribine
• 3) By Dimethyl Fumarate: Tecfidera; Vumerity
• 4) By Fingolimod: Gilenya Fingolimod; Generic Fingolimod
• 5) By Ozanimod: Zeposia
• 6) By Other Drug Types: Natalizumab; Alemtuzumab; Ocrelizumab; Siponimod; Teriflunomide
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Relapsing-Remitting Multiple Sclerosis Market Characteristics

3. Relapsing-Remitting Multiple Sclerosis Market Trends And Strategies

4. Relapsing-Remitting Multiple Sclerosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Relapsing-Remitting Multiple Sclerosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Relapsing-Remitting Multiple Sclerosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Relapsing-Remitting Multiple Sclerosis Market Growth Rate Analysis
• 5.4. Global Relapsing-Remitting Multiple Sclerosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Relapsing-Remitting Multiple Sclerosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Relapsing-Remitting Multiple Sclerosis Total Addressable Market (TAM)

6. Relapsing-Remitting Multiple Sclerosis Market Segmentation

• 6.1. Global Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta-Interferon
• Cladribine
• Dimethyl Fumarate
• Fingolimod
• Ozanimod
• Other Drug Types
• 6.2. Global Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• 6.3. Global Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulating Drugs
• NrF2 Activators
• Interferons
• Other Treatments
• 6.4. Global Relapsing-Remitting Multiple Sclerosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End-Users
• 6.5. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Beta-Interferon, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon Beta-1a
• Interferon Beta-1b
• 6.6. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Cladribine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Cladribine
• Injectable Cladribine
• 6.7. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Dimethyl Fumarate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tecfidera
• Vumerity
• 6.8. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Fingolimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gilenya Fingolimod
• Generic Fingolimod
• 6.9. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Ozanimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zeposia
• 6.10. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natalizumab
• Alemtuzumab
• Ocrelizumab
• Siponimod
• Teriflunomide

7. Relapsing-Remitting Multiple Sclerosis Market Regional And Country Analysis

• 7.1. Global Relapsing-Remitting Multiple Sclerosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Relapsing-Remitting Multiple Sclerosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market

• 8.1. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Relapsing-Remitting Multiple Sclerosis Market

• 9.1. China Relapsing-Remitting Multiple Sclerosis Market Overview
• 9.2. China Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Relapsing-Remitting Multiple Sclerosis Market

• 10.1. India Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Relapsing-Remitting Multiple Sclerosis Market

• 11.1. Japan Relapsing-Remitting Multiple Sclerosis Market Overview
• 11.2. Japan Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Relapsing-Remitting Multiple Sclerosis Market

• 12.1. Australia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Relapsing-Remitting Multiple Sclerosis Market

• 13.1. Indonesia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Relapsing-Remitting Multiple Sclerosis Market

• 14.1. South Korea Relapsing-Remitting Multiple Sclerosis Market Overview
• 14.2. South Korea Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Relapsing-Remitting Multiple Sclerosis Market

• 15.1. Western Europe Relapsing-Remitting Multiple Sclerosis Market Overview
• 15.2. Western Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Relapsing-Remitting Multiple Sclerosis Market

• 16.1. UK Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Relapsing-Remitting Multiple Sclerosis Market

• 17.1. Germany Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Relapsing-Remitting Multiple Sclerosis Market

• 18.1. France Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Relapsing-Remitting Multiple Sclerosis Market

• 19.1. Italy Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Relapsing-Remitting Multiple Sclerosis Market

• 20.1. Spain Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market

• 21.1. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market Overview
• 21.2. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Relapsing-Remitting Multiple Sclerosis Market

• 22.1. Russia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Relapsing-Remitting Multiple Sclerosis Market

• 23.1. North America Relapsing-Remitting Multiple Sclerosis Market Overview
• 23.2. North America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Relapsing-Remitting Multiple Sclerosis Market

• 24.1. USA Relapsing-Remitting Multiple Sclerosis Market Overview
• 24.2. USA Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Relapsing-Remitting Multiple Sclerosis Market

• 25.1. Canada Relapsing-Remitting Multiple Sclerosis Market Overview
• 25.2. Canada Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Relapsing-Remitting Multiple Sclerosis Market

• 26.1. South America Relapsing-Remitting Multiple Sclerosis Market Overview
• 26.2. South America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Relapsing-Remitting Multiple Sclerosis Market

• 27.1. Brazil Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Relapsing-Remitting Multiple Sclerosis Market

• 28.1. Middle East Relapsing-Remitting Multiple Sclerosis Market Overview
• 28.2. Middle East Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Relapsing-Remitting Multiple Sclerosis Market

• 29.1. Africa Relapsing-Remitting Multiple Sclerosis Market Overview
• 29.2. Africa Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Relapsing-Remitting Multiple Sclerosis Market Competitive Landscape And Company Profiles

• 30.1. Relapsing-Remitting Multiple Sclerosis Market Competitive Landscape
• 30.2. Relapsing-Remitting Multiple Sclerosis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Relapsing-Remitting Multiple Sclerosis Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. Novartis AG
• 31.4. GSK plc
• 31.5. Eli Lilly and Company
• 31.6. Merck KGaA
• 31.7. Viatris Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Biogen Inc.
• 31.10. Eisai Co. Ltd.
• 31.11. Genentech Inc.
• 31.12. Hikma Pharmaceuticals LLC
• 31.13. Glenmark Pharmaceuticals Limited
• 31.14. CinnaGen Co
• 31.15. Zenas BioPharma Inc.

32. Global Relapsing-Remitting Multiple Sclerosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Relapsing-Remitting Multiple Sclerosis Market

34. Recent Developments In The Relapsing-Remitting Multiple Sclerosis Market

35. Relapsing-Remitting Multiple Sclerosis Market High Potential Countries, Segments and Strategies

• 35.1 Relapsing-Remitting Multiple Sclerosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Relapsing-Remitting Multiple Sclerosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Relapsing-Remitting Multiple Sclerosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34947_Relapsing_Remitting_Multiple_Sclerosis_GMR_2025